Medimaging Integrated Solution Inc. AI Stock Analysis
Medimaging Integrated Solution Inc. (6796) AI Stock Analysis
Medimaging Integrated Solution Inc.
(TWSE:6796)
The score is held down primarily by weak financial quality: despite healthy revenue growth, margins have compressed severely, earnings are near break-even, and the company has burned free cash for three straight years while funding the gap with debt that now approaches parity with equity. Technicals reinforce the caution, with the stock trading below all major moving averages and momentum indicators negative. Valuation offers no cushion, as the P/E above 120 reflects depressed earnings and the dividend yield is minimal. Partial offsets include accelerating sales, an improving cash-flow trajectory versus 2024, and a still-substantial equity base.
Medimaging Integrated Solution Inc. (6796) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.99B
- Dividend Yield
- 0.51%
- Average Volume (3M)
- 62.08K
- Price to Earnings (P/E)
- 123.0
- Beta (1Y)
- 0.36
- Revenue Growth
- 12.26%
- EPS Growth
- ―
- Country
- TW
- Employees
- 162
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Medimaging Integrated Solution Inc. Business Overview & Revenue Model
Company Description
Medimaging Integrated Solution Inc. specializes in delivering advanced digital and mobile diagnostic technology. The company engineers and produces a variety of digital handheld diagnostic scopes, alongside their essential auxiliary equipment. A key...
Medimaging Integrated Solution Inc. Financial Statement Overview
Summary
Revenue growth remains strong (NT$661m in 2025, up ~23%), but profitability has eroded sharply: gross margin fell from 57.3% in 2023 to 41.8%, and net margin collapsed to about 1%. Leverage has risen rapidly, with debt up from NT$88m in 2022 to NT$674m in 2025 (~0.9x equity), while return on equity has dropped to roughly 1%. Cash flow is the weakest element — operating cash flow was negative in both 2024 and 2025 and free cash flow has been negative for three consecutive years, with the shortfall funded by new borrowing. Modest improvement versus 2024 in operating profit and cash burn provides some offset.
Income Statement
43NeutralBalance Sheet
48NeutralCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 682.01M | 661.39M | 538.92M | 537.15M | 502.09M | 485.87M |
| Gross Profit | 265.52M | 276.55M | 234.32M | 307.76M | 254.39M | 255.72M |
| EBITDA | 65.74M | 74.50M | 50.91M | 119.38M | 118.98M | 114.93M |
| Net Income | 14.32M | 7.72M | 5.61M | 74.05M | 70.02M | 66.48M |
Balance Sheet | ||||||
| Total Assets | 1.65B | 1.57B | 1.36B | 1.34B | 841.41M | 715.84M |
| Cash, Cash Equivalents and Short-Term Investments | 617.44M | 546.57M | 380.18M | 658.35M | 335.11M | 234.26M |
| Total Debt | 453.18M | 674.22M | 443.15M | 405.08M | 87.67M | 135.50M |
| Total Liabilities | 801.99M | 826.34M | 613.67M | 548.13M | 193.26M | 229.72M |
| Stockholders Equity | 852.27M | 745.37M | 742.47M | 792.50M | 648.15M | 486.12M |
Cash Flow | ||||||
| Free Cash Flow | -73.24M | -53.26M | -175.90M | -30.91M | 62.05M | 15.13M |
| Operating Cash Flow | -40.51M | -16.16M | -50.40M | 168.42M | 112.79M | 45.95M |
| Investing Cash Flow | -204.13M | -39.65M | 7.73M | -328.68M | -102.63M | -19.82M |
| Financing Cash Flow | 320.28M | 219.85M | -57.06M | 359.80M | 40.36M | 23.69M |
Medimaging Integrated Solution Inc. Peers Comparison
Overall Rating
TW:652773Outperform
TW:305269Neutral
TW:413868Neutral
TW:411662Neutral- TW:679640Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6527 | 73Outperform | TWD 1.86B | 12.15 | ― | 3.98% | -1.23% | 10.20% |
| TW:3052 | 69Neutral | TWD 2.12B | 9.38 | ― | 5.71% | 9.24% | -3.77% |
| TW:4138 | 68Neutral | TWD 2.15B | 15.66 | ― | 7.75% | -1.10% | -16.90% |
| TW:4116 | 62Neutral | TWD 1.82B | 2.38 | ― | 4.91% | 3.85% | 786.65% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6796 | 40Underperform | TWD 2.04B | 123.00 | ― | 0.51% | 12.26% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6796 | Medimaging Integrated Solution Inc. | 49.20 | -40.22 | -44.98% | |
| TW:3052 | Apex Science & Engineering Corp. | 10.50 | -0.29 | -2.65% | |
| TW:4116 | BenQ Medical Technology Corp. | 40.70 | -3.48 | -7.87% | |
| TW:4138 | Dynamic Medical Technologies Inc. | 54.20 | -5.51 | -9.23% | |
| TW:6527 | Crystalvue Medical Co Ltd | 72.90 | -5.63 | -7.16% | |
| TW:7881 | Eyecare Tech, Inc. | 73.20 | -35.89 | -32.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026